|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
WO2003048197A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Crucell Holland B.V. |
Production and of viruses, viral isolates and vaccines
|
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7425437B2
(en)
*
|
1999-11-26 |
2008-09-16 |
Crucell Holland B.V. |
Vaccines against West Nile Virus
|
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
|
AU2002224199A1
(en)
*
|
2001-10-29 |
2003-06-23 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
CA2756610C
(en)
|
2001-10-29 |
2015-08-25 |
Crucell Holland B.V. |
Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
|
|
EP1465987B1
(en)
*
|
2001-12-07 |
2008-01-23 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
|
SI1456238T1
(sl)
|
2001-12-17 |
2008-08-31 |
Crucell Holland Bv |
Proizvodnja f(ab)2 fragmentov v sesalskih celicah
|
|
KR100454016B1
(ko)
*
|
2002-01-05 |
2004-10-26 |
한국과학기술원 |
항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
|
|
CA2476538C
(en)
*
|
2002-01-09 |
2012-07-17 |
Crucell Holland B.V. |
Use of erythropoietin for the preventive or curative treatment of cardiac failure
|
|
US8287864B2
(en)
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
KR101033196B1
(ko)
|
2002-02-14 |
2011-05-09 |
이뮤노메딕스, 인코오포레이티드 |
항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
|
|
ATE477276T1
(de)
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
|
AU2002307635A1
(en)
*
|
2002-04-19 |
2003-11-03 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
CN1675245B
(zh)
|
2002-06-14 |
2011-01-12 |
免疫医疗公司 |
人源化单克隆抗体hPAM4
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CN105884893A
(zh)
|
2002-07-18 |
2016-08-24 |
莫鲁斯有限公司 |
抗体混合物的重组生产
|
|
CA2494310A1
(en)
|
2002-08-01 |
2004-02-12 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
US8524477B2
(en)
|
2002-10-29 |
2013-09-03 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
CA2520891C
(en)
*
|
2003-05-09 |
2014-07-08 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
|
CA2521490C
(en)
*
|
2003-05-23 |
2013-07-30 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
EP1636265A2
(en)
|
2003-06-25 |
2006-03-22 |
Crucell Holland B.V. |
Binding molecules for the treatment of myeloid cell malignancies
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1508576A1
(en)
*
|
2003-08-20 |
2005-02-23 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
EP1670925B1
(en)
|
2003-10-02 |
2013-05-01 |
Crucell Holland B.V. |
Packaging cells for recombinant adenovirus
|
|
WO2005059149A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Chromagenics B.V. |
Improved protein production
|
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
|
AU2005229359C1
(en)
*
|
2004-03-05 |
2011-07-28 |
Patheon Holdings I B.V. |
Process for cell culturing by continuous perfusion and alternating tangential flow
|
|
CN102139106B
(zh)
|
2004-05-27 |
2014-10-08 |
克鲁塞尔荷兰公司 |
能中和狂犬病病毒的结合分子及其应用
|
|
EP1799259B1
(en)
|
2004-10-12 |
2012-12-05 |
Crucell Holland B.V. |
Binding molecules for the detection of cancer
|
|
EA010863B1
(ru)
|
2004-11-08 |
2008-12-30 |
Хромагеникс Б.В. |
Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях
|
|
NZ553701A
(en)
|
2004-11-11 |
2009-12-24 |
Crucell Holland Bv |
Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
|
|
CA2591665C
(en)
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8052974B2
(en)
|
2005-05-12 |
2011-11-08 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
|
EP1739179A1
(en)
*
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
|
EP2455100A3
(en)
*
|
2005-11-07 |
2012-11-07 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
|
US8470318B2
(en)
|
2005-11-07 |
2013-06-25 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
WO2008057634A2
(en)
*
|
2006-10-26 |
2008-05-15 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
US20080206246A1
(en)
*
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
AR053416A1
(es)
*
|
2005-11-10 |
2007-05-09 |
Protech Pharma S A |
Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
US7642078B2
(en)
|
2005-12-28 |
2010-01-05 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
EP1996705B1
(en)
|
2006-03-20 |
2011-08-31 |
ChromaGenics B.V. |
Expression augmenting dna fragments, use thereof, and methods for finding thereof
|
|
CN101432301B
(zh)
|
2006-04-05 |
2014-01-08 |
洛克菲勒大学 |
具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法
|
|
JP5574706B2
(ja)
|
2006-06-06 |
2014-08-20 |
クルセル ホランド ベー ヴェー |
ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
|
|
KR20200058579A
(ko)
|
2006-06-06 |
2020-05-27 |
얀센 백신스 앤드 프리벤션 비.브이. |
장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
|
|
ES2650042T3
(es)
|
2006-07-14 |
2018-01-16 |
Patheon Holdings I B.V. |
Proceso mejorado para el cultivo de células
|
|
MX343198B
(es)
|
2006-09-07 |
2016-10-11 |
Crucell Holland Bv |
Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas.
|
|
EA017203B1
(ru)
|
2006-09-07 |
2012-10-30 |
Круселл Холланд Б.В. |
Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
EP3176263A1
(en)
|
2007-08-10 |
2017-06-07 |
Toto Ltd. |
Method of producing recombinant mammalian cells
|
|
WO2009074318A2
(en)
*
|
2007-12-13 |
2009-06-18 |
Roche Diagnostics Gmbh |
Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
|
|
US20120039939A1
(en)
*
|
2008-04-11 |
2012-02-16 |
The Johns Hopkins University |
Compositions and methods for vaccine and virus production
|
|
EP2279410B1
(en)
|
2008-04-22 |
2015-11-11 |
The Rockefeller University |
Methods of identifying anti-inflammatory compounds
|
|
DK2307538T3
(da)
*
|
2008-07-15 |
2016-01-18 |
Crucell Holland Bv |
Skalérbar fremgangsmåde til dyrkning af per.c6-celler og fremstilling af produkter derfra
|
|
AU2009274129B2
(en)
|
2008-07-21 |
2016-02-25 |
Immunomedics Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
EP2421895B1
(en)
|
2009-04-23 |
2015-11-11 |
Crucell Holland B.V. |
Recombinant human alpha1-antitrypsin
|
|
WO2010130636A1
(en)
|
2009-05-11 |
2010-11-18 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
|
US20120270264A1
(en)
|
2009-10-01 |
2012-10-25 |
Toto Ltd. |
Dna construct, and process for production of recombinant cho cell using same
|
|
ES2603559T5
(es)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US8961978B2
(en)
|
2011-07-14 |
2015-02-24 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
|
|
FI3865581T3
(fi)
|
2011-08-05 |
2024-11-02 |
Regeneron Pharma |
Humanisoituja universaaleja kevytketjun hiiriä
|
|
AU2012340501A1
(en)
|
2011-12-19 |
2013-07-11 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
CN102827273A
(zh)
*
|
2012-02-16 |
2012-12-19 |
张小莺 |
抗痘苗病毒IgY抗体的制备
|
|
US8834881B2
(en)
|
2012-03-08 |
2014-09-16 |
Crucell Holland B.V. |
Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
|
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
|
US9657290B2
(en)
|
2012-07-03 |
2017-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Scalable bio-element analysis
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
KR20150070181A
(ko)
|
2012-09-27 |
2015-06-24 |
크루셀 홀란드 비.브이. |
B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
|
|
PL2900694T3
(pl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Dwuswoiste przeciwciała igg jako aktywatory komórek t
|
|
AU2014255865B2
(en)
|
2013-04-15 |
2019-07-18 |
Janssen Vaccines & Prevention B.V. |
Human antibodies binding to RSV G proteins
|
|
KR102201554B1
(ko)
|
2013-04-15 |
2021-01-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
Ｒｓｖ ｇ 단백질에 결합하는 인간 항체
|
|
DE112014003136A5
(de)
|
2013-07-01 |
2016-04-21 |
Charité - Universitätsmedizin Berlin |
Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
|
|
CN104693308B
(zh)
*
|
2013-12-05 |
2020-08-04 |
同济大学 |
感受胞内pH变化的Smad5蛋白及其应用
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
RS66392B1
(sr)
|
2014-02-28 |
2025-02-28 |
Merus Nv |
Antitelo koje vezuje erbb-2 i erbb-3
|
|
ES2816624T3
(es)
|
2014-02-28 |
2021-04-05 |
Merus Nv |
Anticuerpos que se unen a EGFR y ERBB3
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
TW202204596A
(zh)
|
2014-06-06 |
2022-02-01 |
美商健臻公司 |
灌注培養方法及其用途
|
|
US10174127B2
(en)
|
2015-02-05 |
2019-01-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
|
EA038407B1
(ru)
|
2015-02-05 |
2021-08-24 |
Янссен Вэксинс Энд Превеншн Б.В. |
Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
|
|
JP6920997B2
(ja)
|
2015-02-22 |
2021-08-18 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
マイクロスクリーニング装置、プロセス、及び生成物
|
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
LT3115376T
(lt)
|
2015-07-10 |
2018-11-12 |
Merus N.V. |
Antikūnai, kurie jungiasi su žmogaus cd3
|
|
US11939394B2
(en)
|
2015-10-23 |
2024-03-26 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
|
WO2017148889A1
(en)
|
2016-03-01 |
2017-09-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza b neuraminidase
|
|
CN110198786A
(zh)
|
2016-11-14 |
2019-09-03 |
浩康生物系统公司 |
用于分选目标颗粒的方法和装置
|
|
WO2018178077A1
(en)
|
2017-03-28 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
IL269656B2
(en)
|
2017-03-31 |
2024-06-01 |
Merus Nv |
Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
|
|
CA3058290A1
(en)
|
2017-04-18 |
2018-10-25 |
Universite Libre De Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
EP3625264B9
(en)
|
2017-05-17 |
2023-10-25 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
PL3665198T3
(pl)
|
2017-08-09 |
2025-06-09 |
Merus N.V. |
Przeciwciała wiążące egfr i cmet
|
|
EP3693013A4
(en)
|
2017-10-06 |
2021-06-30 |
Ono Pharmaceutical Co., Ltd. |
BISPECIFIC ANTIBODY
|
|
AU2018380765A1
(en)
|
2017-12-04 |
2020-06-11 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
KR20200116105A
(ko)
|
2018-02-01 |
2020-10-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
타우에 특이적으로 결합하는 결합 분자
|
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
KR102879500B1
(ko)
|
2018-03-23 |
2025-10-31 |
유니베르시테 리브레 드 브룩크젤즈 |
Wnt 시그널링 작용제 분자
|
|
TW202509079A
(zh)
|
2019-04-04 |
2025-03-01 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
US20220372148A1
(en)
|
2019-07-05 |
2022-11-24 |
Ono Pharmaceutical Co., Ltd. |
A pharmaceutical composition for treating hematological cancer
|
|
CA3149309A1
(en)
|
2019-07-30 |
2021-02-04 |
Ono Pharmaceutical Co., Ltd. |
Bispecific antibody
|
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
US20220403401A1
(en)
*
|
2021-06-11 |
2022-12-22 |
Monsanto Technology Llc |
Methods and compositions for altering protein accumulation
|
|
KR20250052397A
(ko)
|
2022-08-23 |
2025-04-18 |
오노 야꾸힝 고교 가부시키가이샤 |
이중 특이성 항체
|